By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eleven Biotherapeutics 

215 First Street
Suite 400
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-871-9911 Fax: 617-858-0911


SEARCH JOBS

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.

YEAR FOUNDED:

2000

LEADERSHIP:

Founder: Reza Dana, K. Christopher Garcia, Greg Verdine, Casey Weaver, K. Dane Wittrup

CEO: Abbie Celniker

CMO (Medical): Michael Goldstein

JOBS:

Please click here for Eleven Biotherapeutics.


Key Statistics


Email: info@elevenbio.com
Ownership: Public

Web Site: Eleven Bio
Employees:
Symbol: EBIO
 



Industry
Pharmaceutical






Company News
Eleven Bio (EBIO) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9/23/2016 10:13:30 AM
Eleven Bio (EBIO) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9/22/2016 12:06:40 PM
Struggling Eleven Bio (EBIO) Scoops Up Canadian Biotech, CEO Steps Down 9/21/2016 6:31:21 AM
Roche (RHHBY), Eleven Bio (EBIO) Ink $270 Million Exclusive Licensing Deal 8/16/2016 7:09:39 AM
Struggling Eleven Bio (EBIO) Explores Sale of the Company 8/12/2016 8:33:55 AM
Eleven Bio (EBIO) Announces Effectiveness Of Investigational New Drug Application For EBI-031 7/8/2016 10:53:44 AM
2 Fallen Biotech Stocks Worth Chasing 7/7/2016 8:01:17 AM
Cambridge's Eleven Bio (EBIO) Pink Slips 70% of Workforce in Restructuring 6/23/2016 5:57:38 AM
Eleven Bio (EBIO) Announces Investigational New Drug Application Submission To Initiate Clinical Trials Of EBI-031 For Ocular Diseases 6/13/2016 10:24:35 AM
Struggling Eleven Bio (EBIO) Forges Deal Worth $270 Million with Pharma Giant Roche (RHHBY) 6/13/2016 6:32:59 AM
123456789
//-->